

Exosomes - Pipeline Insight, 2022

<https://marketpublishers.com/r/EE43B8255305EN.html>

Date: January 2022

Pages: 200

Price: US\$ 2,500.00 (Single User License)

ID: EE43B8255305EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Exosomes - Pipeline Insight, 2022" report provides comprehensive insights about 55+ companies and 70+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Exosomes Understanding

Exosomes: Overview

Exosomes are a type of extracellular vesicle, a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages that contain constituents (protein, DNA, and RNA) of the cells that secrete them. Exosomes can be a highly heterogeneous population and have distinct abilities to induce a complex biological response. Exosomes are isolated from a wide spectrum of biological fluids, including blood, urine, saliva and breast milk. Exosomes are generated in a process that involves double invagination of the plasma membrane and the formation of intracellular multivesicular bodies containing intraluminal vesicles. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes have therapeutic potential to control many diseases, along with aid in disease diagnosis. Extensive studies are going on for

the role of exosomes in the diagnosis and treatment of various pathologies.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches for Exosomes.

Exosomes Emerging Drugs Chapters

This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs

ExoFlo: Direct Biologics

ExoFlo is an investigational new drug that has not been approved or licensed by the FDA. It is an extracellular vesicle product isolated from human bone marrow mesenchymal stem or stromal cells (MSCs). The drug is in Phase II clinical development for the treatment of Covid19, ARDS, and viral pneumonia. In October 2020, The US Food and Drug Administration (FDA) granted expanded access for Direct Biologics' ExoFlo, allowing it to be used to treat patients with COVID-19-associated acute respiratory distress syndrome. It is currently in phase II stage of development and is being developed by Direct Biologics.

Progenza: Regeneus

Progenza is being developed by Regeneus, and is currently in the Phase II stage of development for Osteoarthritis and preclinical for Neuropathic Pain. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue but the Mesenchymal Signalling Cells (MSCs) themselves.

Further product details are provided in the report.....

Exosomes: Therapeutic Assessment

This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Exosomes

There are approx. 55+ key companies which are developing the Exosomes. The companies which have their Exosomes drug candidates in the most advanced stage, i.e. Phase II include, Direct Biologics.

Phases

DelveInsight's report covers around 70+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exosomes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I,

preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Exosomes Report Insights

- Exosomes Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Exosomes Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Exosomes drugs?

- How many Exosomes drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Exosomes?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Exosomes and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Direct Biologics

Capricor

Regeneus

AVEM HealthCare

Aegle Therapeutics

Organicell Regenerative Medicine

Codiak Biosciences

United Therapeutics

ArunA Biomedical

Evox Therapeutics

ArunA Biomedical

MolecuVax

Versatope Therapeutics

Lamellar Biomedical

Azymus Therapeutics

Alxerion Biotech

Avalon GloboCare

Capricor Therapeutics

Key Products

ExoFlo

CAP-1002

Progenza

Mesenchymal stem cells (MSCs) exosomes

AGLE 102

Zofin

exoIL-12

exoSTING

UNEX 42

AB 126

EVX-102

AB 127

EVX-101

AB 128

MVAX 001

VT 105

IPF-Lamellosome

Muco-ease

AZ-001

ALX-029

ALX-102

AVA-201

CAP 2003

AVA 203

Contents

- Introduction
- Executive Summary
- Exosomes: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
- Late Stage Products (Phase III)
 - Comparative Analysis
- Drug name: Company name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- ExoFlo: Direct Biologics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- UNEX 42: United Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
 - Comparative Analysis
- EVX-102: Evox Therapeutics
 - Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Exosomes Key Companies
Exosomes Key Products
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Exosomes- Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Exosomes

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Exosomes
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Exosomes - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/EE43B8255305EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EE43B8255305EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970